Cited by 12vaccines and immunoinformatics approachesImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

NetMHCphosPan - Pan-specific prediction of MHC class I antigen presentation of phosphorylated ligands

Open access

Abstract

Post-translational modifications of proteins play a crucial part in carcinogenesis. Phosphorylated peptides have shown to be presented by MHC class I molecules and recognised by cytotoxic T cells, making them a promising target for immunotherapy. Identification of phosphorylated MHC class I ligands has so far predominantly been done using bioinformatic tools trained on unmodified peptides. Only one tool, PhosMHCpred, has been developed specifically for the prediction of phosphorylated MHC class I ligands so far and this tool has been trained only on a limited number of alleles and provides a limited peptide length coverage (only including 9-mers). Here we propose a method, termed NetMHCphosPan, for the prediction of MHC presented phosphopeptides. The method is trained using the NNAlign_MA framework, which allows incorporating mixed data types and information leverage between data sets resulting in a greatly improved MHC and peptide length coverage and an overall increased predictive power compared to PhosMHCpred. Motif deconvolution suggested a strong preference for phosphosites to be located in position 4 of the binding motif, and enrichment of proline at P5 and arginine at P1. The improved performance, driven by the extended length and allelic coverage, of NetMHCphosPan over current state-of-the-art methods, was further validated on a large benchmark data set independent from the model development. In conclusion, we have confirmed the high power of NNAlign_MA for motif deconvolution of complex immuno-peptidomics data and have developed a novel method for prediction of MHC presented phosphopeptides with improved predictive power and a broader peptide length and MHC coverage compared to current state-of-the-art methods. The developed method is available at http://www.cbs.dtu.dk/services/NetMHCphosPan-1.0.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuno.2021.100005

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. Andersen, 1999, Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL, J Immunol Baltim Md 1950. 1. oktober, 163, 3812
  2. Zarling, 2000, Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo, J Exp Med, 192, 1755, 10.1084/jem.192.12.1755 · DOI · Paper page
  3. Zarling, 2006, Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy, Proc Natl Acad Sci. 3. oktober, 103, 14889, 10.1073/pnas.0604045103 · DOI
  4. Robinson, 2019, IPD-IMGT/HLA database, Nucleic Acids Res., 31, gkz950, 10.1093/nar/gkz950 · DOI
  5. Nielsen, 2020, Immunoinformatics: predicting peptide–MHC binding, Annu Rev Biomed Data Sci. 20. juli, 3, 191, 10.1146/annurev-biodatasci-021920-100259 · DOI
  6. Alpízar, 2017, A molecular basis for the presentation of phosphorylated peptides by HLA-B antigens, Mol Cell Proteomics MCP. februar, 16, 181, 10.1074/mcp.M116.063800 · DOI
  7. Meyer, 2009, Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands, J Proteome Res. 6. juli, 8, 3666, 10.1021/pr800937k · DOI
  8. Cobbold, 2013, MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia, Sci Transl Med, 5, 10.1126/scitranslmed.3006061 · DOI
  9. Marcilla, 2014, Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue*, Mol Cell Proteomics. februar, 13, 462, 10.1074/mcp.M113.034314 · DOI
  10. Bassani-Sternberg, 2016, Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry, Nat Commun, 7, 13404, 10.1038/ncomms13404 · DOI · Paper page
  11. Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity. februar, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI
  12. Mohammed, 2008, Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self, Nat Immunol, 9, 1236, 10.1038/ni.1660 · DOI · Paper page
  13. Mohammed, 2017, The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status, Oncotarget, 8, 54160, 10.18632/oncotarget.16952 · DOI
  14. Mommen, 2014, Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD), Proc Natl Acad Sci. 25. marts, 111, 4507, 10.1073/pnas.1321458111 · DOI
  15. Solleder, 2020, Mass spectrometry based immunopeptidomics leads to robust predictions of phosphorylated HLA Class I Ligands, Mol Cell Proteomics MCP. februar, 19, 390, 10.1074/mcp.TIR119.001641 · DOI · Paper page
  16. Alvarez, 2019, NNAlign_MA; MHC peptidome deconvolution for accurate MHC binding motif characterization and improved T-cell epitope predictions, Mol Cell Proteomics, 18, 2459, 10.1074/mcp.TIR119.001658 · DOI
  17. Hornbeck, 2015, PhosphoSitePlus, 2014: mutations, PTMs and recalibrations, Nucleic Acids Res. januar, 43, D512, 10.1093/nar/gku1267 · DOI · Paper page
  18. Reynisson, 2020, NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucleic Acids Res. 2. juli, 48, W449, 10.1093/nar/gkaa379 · DOI · Paper page
  19. Nielsen, 2007, Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method, BMC Bioinformatics. 4. juli, 8, 238, 10.1186/1471-2105-8-238 · DOI
  20. Mei, 2020, Immunopeptidomic analysis reveals that deamidated HLA-bound peptides arise predominantly from deglycosylated precursors, Mol Cell Proteomics. juli, 19, 1236, 10.1074/mcp.RA119.001846 · DOI
  21. Purcell, 2019, Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics, Nat Protoc. juni, 14, 1687, 10.1038/s41596-019-0133-y · DOI
  22. Wagih, 2017, ggseqlogo: a versatile R package for drawing sequence logos, Hancock J, redaktør. Bioinformatics, 33, 3645, 10.1093/bioinformatics/btx469 · DOI
  23. Sharma, 2014, Ultradeep Human Phosphoproteome Reveals a Distinct Regulatory Nature of Tyr and Ser/Thr-Based Signaling, Cell Rep, 8, 1583, 10.1016/j.celrep.2014.07.036 · DOI
  24. Fenoy, 2019, A generic deep convolutional neural network framework for prediction of receptor-ligand interactions-NetPhosPan: application to kinase phosphorylation prediction, Bioinforma Oxf Engl, 35, 1098, 10.1093/bioinformatics/bty715 · DOI
  25. Hoof, 2009, NetMHCpan, a method for MHC class I binding prediction beyond humans, Immunogenetics. januar, 61, 1, 10.1007/s00251-008-0341-z · DOI
  26. Leko, 2020, Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors, Cancer Cell. 12. oktober, 38, 454, 10.1016/j.ccell.2020.07.013 · DOI · Paper page
  27. Engelhard, 2020, MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma, J Immunother Cancer. maj, 8

Metadata

Authors
Refsgaard, C. T., Barra, C., Peng, X., Ternette, N., & Nielsen, M.
Affiliations
  • Technical University of Denmark (DK)
  • University of Oxford (GB)
  • National University of General San Martín (AR)
Corresponding author
Nielsen, Morten
Venue
ImmunoInformatics
Publisher
Elsevier BV
Published
2021-10
Volume
1-2
Pages
100005
ISSN
2667-1190 (ISSN-L)
OpenAlex
W3195507843
Cited by
12
References
1
Citations by year
2026: 4 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3
FWCI
0.55
Type
journal article
Language
en
Open access
Locations
  • ImmunoInformatics (publishedVersion, cc-by-nc-nd)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institute of Allergy and Infectious Diseases (HHSN272201200010C)
  • National Institutes of Health
  • U.S. Department of Health and Human Services
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
MHC class I antigen presentation, phosphopeptides, post-translational modification, MHC alleles, cancer immunotherapy, cytotoxic T lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review